目次

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 29)
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED
1.3.3 CURRENCY CONSIDERED
1.4 RESEARCH LIMITATIONS
1.5 STAKEHOLDERS
1.6 RECESSION IMPACT

2 RESEARCH METHODOLOGY (Page No. - 33)
2.1 RESEARCH DATA
FIGURE 1 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
FIGURE 2 MONOCLONAL ANTIBODY THERAPEUTICS MARKET: BREAKDOWN OF PRIMARIES
2.2 MARKET SIZE ESTIMATION
FIGURE 3 MONOCLONAL ANTIBODY THERAPEUTICS: MARKET SIZE ESTIMATION (SUPPLY SIDE ANALYSIS), 2023
FIGURE 4 MONOCLONAL ANTIBODY THERAPEUTICS: MARKET SIZE ESTIMATION (PRODUCT-BASED ANALYSIS), 2023
FIGURE 5 MARKET SIZE ESTIMATION: APPROACH 1 (REVENUE SHARE ANALYSIS), 2023
FIGURE 6 ILLUSTRATIVE EXAMPLE OF F. HOFFMANN-LA ROCHE AG: REVENUE SHARE ANALYSIS, 2023
2.2.1 INSIGHTS FROM PRIMARIES
FIGURE 7 MARKET VALIDATION FROM PRIMARY EXPERTS
2.2.2 SEGMENT ASSESSMENT (BY PRODUCTION METHOD, SOURCE, ROUTE OF ADMINISTRATION, THERAPY AREA, AND END USER)
FIGURE 8 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
2.3 GROWTH RATE ASSUMPTIONS
FIGURE 9 MONOCLONAL ANTIBODY THERAPEUTICS INDUSTRY: CAGR PROJECTIONS, 2024-2029
FIGURE 10 MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, CHALLENGES, AND OPPORTUNITIES
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 11 DATA TRIANGULATION METHODOLOGY
2.5 STUDY ASSUMPTIONS
2.6 RISK ANALYSIS
2.7 RECESSION IMPACT ANALYSIS

3 EXECUTIVE SUMMARY (Page No. - 46)
FIGURE 12 MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2024 VS. 2029 (USD MILLION)
FIGURE 13 MONOCLONAL ANTIBODY THERAPEUTICS INDUSTRY, BY ROUTE OF ADMINISTRATION, 2024 VS. 2029 (USD MILLION)
FIGURE 14 MARKET, BY THERAPY TYPE, 2024 VS. 2029 (USD MILLION)
FIGURE 15 MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
FIGURE 16 GEOGRAPHICAL SNAPSHOT OF MARKET

4 PREMIUM INSIGHTS (Page No. - 50)
4.1 MONOCLONAL ANTIBODY THERAPEUTICS MARKET OVERVIEW
FIGURE 17 ADVANCEMENTS IN BIOTECHNOLOGY AND GENETIC ENGINEERING TO DRIVE MARKET DURING FORECAST PERIOD
4.2 NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS INDUSTRY, BY PRODUCTION METHOD (2023)
FIGURE 18 IN-VITRO PRODUCTION METHOD ACCOUNTED FOR LARGEST MARKET SHARE IN 2023
4.3 MARKET, BY SOURCE, 2024 VS. 2029 (USD MILLION)
FIGURE 19 HUMAN SOURCE SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE DURING FORECAST PERIOD
4.4 MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 20 GERMANY TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD

5 MARKET OVERVIEW (Page No. - 53)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 21 MONOCLONAL ANTIBODY THERAPEUTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Advancements in biotechnology and genetic engineering
5.2.1.2 Increasing demand for personalized medicine
5.2.1.3 Growing product pipeline of mAb therapeutics
FIGURE 22 NUMBER OF ANTIBODY THERAPEUTICS GRANTED FIRST APPROVAL IN US/EU (2012−2023)
5.2.2 RESTRAINTS
5.2.2.1 Stringent regulatory approval process
5.2.2.2 High cost of mAb treatments
5.2.3 OPPORTUNITIES
5.2.3.1 Innovative therapeutic indications
5.2.3.2 Rising technological advancements in antibody engineering
5.2.4 CHALLENGES
5.2.4.1 Rising development & production costs
5.3 PORTER’S FIVE FORCES ANALYSIS
TABLE 1 MONOCLONAL ANTIBODY THERAPEUTICS INDUSTRY: PORTER’S FIVE FORCES ANALYSIS
5.3.1 THREAT OF NEW ENTRANTS
5.3.2 THREAT OF SUBSTITUTES
5.3.3 BARGAINING POWER OF SUPPLIERS
5.3.4 BARGAINING POWER OF BUYERS
5.3.5 INTENSITY OF COMPETITIVE RIVALRY
5.4 TECHNOLOGY ANALYSIS
5.4.1 CONVENTIONAL PRODUCTION OF MABS
5.4.2 TECHNOLOGICAL ADVANCEMENTS FOR MABS
TABLE 2 MARKET: TECHNOLOGY COMPARISON
5.5 VALUE CHAIN ANALYSIS
FIGURE 23 MARKET: VALUE CHAIN
5.6 PATENT ANALYSIS
5.6.1 METHODOLOGY
5.6.2 PATENTS FILED BY DOCUMENT TYPE, 2014-2023
TABLE 3 PATENTS FILED, 2014-2023
5.6.3 INNOVATION AND PATENT APPLICATIONS
FIGURE 24 TOTAL NUMBER OF PATENTS GRANTED, 2014-2023
5.6.4 TOP APPLICANTS
FIGURE 25 TOP TEN PLAYERS WITH HIGHEST NUMBER OF PATENT APPLICATIONS, 2014-2023
FIGURE 26 REGIONAL ANALYSIS OF PATENTS GRANTED, 2014-2023
TABLE 4 TOP 10 PATENT OWNERS IN MARKET, 2013-2023
TABLE 5 PATENTS IN MARKET, 2023−2024
5.7 KEY CONFERENCES & EVENTS
TABLE 6 MARKET: DETAILED LIST OF CONFERENCES & EVENTS (2024-2025)
5.8 INVESTMENT AND FUNDING SCENARIO
5.9 PIPELINE ANALYSIS
TABLE 7 MONOCLONAL ANTIBODY THERAPEUTICS IN CLINICAL PIPELINE
5.10 SUPPLY CHAIN ANALYSIS
FIGURE 27 MARKET: SUPPLY CHAIN ANALYSIS
5.11 ECOSYSTEM ANALYSIS
FIGURE 28 MONOCLONAL ANTIBODY THERAPEUTICS ECOSYSTEM
5.11.1 MONOCLONAL ANTIBODY THERAPEUTIC VENDORS
TABLE 8 MONOCLONAL ANTIBODY THERAPEUTIC VENDORS
5.11.2 END USERS OF MONOCLONAL ANTIBODY THERAPEUTICS
TABLE 9 MONOCLONAL ANTIBODY THERAPEUTIC END USERS
5.11.3 REGULATORY BODIES FOR MONOCLONAL ANTIBODY THERAPEUTICS
TABLE 10 MONOCLONAL ANTIBODY THERAPEUTIC REGULATORY BODIES
5.12 REGULATORY LANDSCAPE
5.12.1 REGULATORY ANALYSIS
5.12.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 11 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 12 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 13 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 14 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.13 PRICING ANALYSIS
5.13.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS
TABLE 15 AVERAGE SELLING PRICE OF MONOCLONAL ANTIBODY THERAPEUTICS IN US
5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
FIGURE 29 TECHNOLOGICAL ADVANCEMENTS IN MONOCLONAL ANTIBODY PRODUCTION TO DRIVE MARKET GROWTH
5.15 KEY STAKEHOLDERS AND BUYING CRITERIA
5.15.1 KEY STAKEHOLDERS ON BUYING PROCESS
FIGURE 30 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR MABS AMONG TOP TWO END USERS
TABLE 16 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP TWO END USERS
5.15.2 BUYING CRITERIA FOR MONOCLONAL ANTIBODY THERAPEUTICS
FIGURE 31 KEY BUYING CRITERIA FOR HOSPITALS AND LONG-TERM CARE FACILITIES
TABLE 17 KEY BUYING CRITERIA FOR TOP TWO END USERS

6 MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD (Page No. - 88)
6.1 INTRODUCTION
TABLE 18 MONOCLONAL ANTIBODY THERAPEUTICS INDUSTRY, BY PRODUCTION METHOD, 2022-2029 (USD MILLION)
6.2 IN-VITRO PRODUCTION
6.2.1 HIGH SCALABILITY AND COST EFFICIENCY TO PROPEL MARKET
TABLE 19 MARKET FOR IN-VITRO PRODUCTION, BY REGION, 2022-2029 (USD MILLION)
TABLE 20 NORTH AMERICA: MARKET FOR IN-VITRO PRODUCTION, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 21 EUROPE: MARKET FOR IN-VITRO PRODUCTION, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 22 ASIA PACIFIC: MARKET FOR IN-VITRO PRODUCTION, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 23 LATIN AMERICA: MARKET FOR IN-VITRO PRODUCTION, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 24 MIDDLE EAST: MARKET FOR IN-VITRO PRODUCTION, BY REGION, 2022-2029 (USD MILLION)
TABLE 25 GCC COUNTRIES: MARKET FOR IN-VITRO PRODUCTION, BY COUNTRY, 2022-2029 (USD MILLION)
6.3 IN-VIVO PRODUCTION
6.3.1 MINIMAL SIDE-EFFECTS TO SUPPORT MARKET GROWTH
TABLE 26 MARKET FOR IN-VIVO PRODUCTION, BY REGION, 2022-2029 (USD MILLION)
TABLE 27 NORTH AMERICA: MARKET FOR IN-VIVO PRODUCTION, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 28 EUROPE: MARKET FOR IN-VIVO PRODUCTION, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 29 ASIA PACIFIC: MARKET FOR IN-VIVO PRODUCTION, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 30 LATIN AMERICA: MARKET FOR IN-VIVO PRODUCTION, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 31 MIDDLE EAST: MARKET FOR IN-VIVO PRODUCTION, BY REGION, 2022-2029 (USD MILLION)
TABLE 32 GCC COUNTRIES: MARKET FOR IN-VIVO PRODUCTION, BY COUNTRY, 2022-2029 (USD MILLION)

7 MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION (Page No. - 97)
7.1 INTRODUCTION
TABLE 33 MONOCLONAL ANTIBODY THERAPEUTICS INDUSTRY, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
7.2 INTRAVENOUS ROUTE OF ADMINISTRATION
7.2.1 DIRECT DELIVERY OF THERAPEUTIC DOSAGE FOR MULTIPLE INDICATIONS TO DRIVE MARKET
TABLE 34 MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY REGION, 2022-2029 (USD MILLION)
TABLE 35 NORTH AMERICA: MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 36 EUROPE: MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 37 ASIA PACIFIC: MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 38 LATIN AMERICA: MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 39 MIDDLE EAST: MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY REGION, 2022-2029 (USD MILLION)
TABLE 40 GCC COUNTRIES: MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022-2029 (USD MILLION)
7.3 SUBCUTANEOUS ROUTE OF ADMINISTRATION
7.3.1 ENHANCED PATIENT ADHERENCE AND LOW HEALTHCARE COSTS TO DRIVE MARKET
TABLE 41 MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY REGION, 2022-2029 (USD MILLION)
TABLE 42 NORTH AMERICA: MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 43 EUROPE: MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 44 ASIA PACIFIC: MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 45 LATIN AMERICA: MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 46 MIDDLE EAST: MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY REGION, 2022−2029 USD MILLION)
TABLE 47 GCC COUNTRIES: MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022-2029 (USD MILLION)
7.4 OTHER ROUTES OF ADMINISTRATION
TABLE 48 MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY REGION, 2022-2029 (USD MILLION)
TABLE 49 NORTH AMERICA: MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 50 EUROPE: MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 51 ASIA PACIFIC: MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 52 LATIN AMERICA: MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 53 MIDDLE EAST: MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY REGION, 2022-2029 (USD MILLION)
TABLE 54 GCC COUNTRIES: MARKET FOR OTHER ROUTESC OF ADMINISTRATION, BY COUNTRY, 2022-2029 (USD MILLION)

8 MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE (Page No. - 110)
8.1 INTRODUCTION
TABLE 55 MONOCLONAL ANTIBODY THERAPEUTICS INDUSTRY, BY SOURCE, 2022-2029 (USD MILLION)
8.2 HUMAN SOURCE
8.2.1 REDUCED IMMUNOGENICITY AND IMPROVED EFFICACY TO PROPEL MARKET
TABLE 56 MARKET FOR HUMAN SOURCE, BY REGION, 2022-2029 (USD MILLION)
TABLE 57 NORTH AMERICA: MARKET FOR HUMAN SOURCE, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 58 EUROPE: MARKET FOR HUMAN SOURCE, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 59 ASIA PACIFIC: MARKET FOR HUMAN SOURCE, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 60 LATIN AMERICA: MARKET FOR HUMAN SOURCE, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 61 MIDDLE EAST: MARKET FOR HUMAN SOURCE, BY REGION, 2022-2029 (USD MILLION)
TABLE 62 GCC COUNTRIES: MARKET FOR HUMAN SOURCE, BY COUNTRY, 2022-2029 (USD MILLION)
8.3 HUMANIZED SOURCE
8.3.1 ABILITY TO ADJUST SPECIFICITY AND BIOLOGICAL FUNCTIONS TO DRIVE MARKET
TABLE 63 MARKET FOR HUMANIZED SOURCE, BY REGION, 2022-2029 (USD MILLION)
TABLE 64 NORTH AMERICA: MARKET FOR HUMANIZED SOURCE, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 65 EUROPE: MARKET FOR HUMANIZED SOURCE, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 66 ASIA PACIFIC: MARKET FOR HUMANIZED SOURCE, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 67 LATIN AMERICA: MARKET FOR HUMANIZED SOURCE, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 68 MIDDLE EAST: MARKET FOR HUMANIZED SOURCE, BY REGION, 2022-2029 (USD MILLION)
TABLE 69 GCC COUNTRIES: MARKET FOR HUMANIZED SOURCE, BY COUNTRY, 2022-2029 (USD MILLION)
8.4 CHIMERIC SOURCE
8.4.1 UTILIZATION OF GENETIC ENGINEERING TECHNIQUES FOR MINIMIZED IMMUNOGENIC RESPONSES TO FUEL MARKET
TABLE 70 MARKET FOR CHIMERIC SOURCE, BY REGION, 2022-2029 (USD MILLION)
TABLE 71 NORTH AMERICA: MARKET FOR CHIMERIC SOURCE, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 72 EUROPE: MARKET FOR CHIMERIC SOURCE, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 73 ASIA PACIFIC: MARKET FOR CHIMERIC SOURCE, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 74 LATIN AMERICA: MARKET FOR CHIMERIC SOURCE, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 75 MIDDLE EAST: MARKET FOR CHIMERIC SOURCE, BY REGION, 2022-2029 (USD MILLION)
TABLE 76 GCC COUNTRIES: MARKET FOR CHIMERIC SOURCE, BY COUNTRY, 2022-2029 (USD MILLION)
8.5 OTHER SOURCES
TABLE 77 MARKET FOR OTHER SOURCES, BY REGION, 2022-2029 (USD MILLION)
TABLE 78 NORTH AMERICA: MARKET FOR OTHER SOURCES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 79 EUROPE: MARKET FOR OTHER SOURCES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 80 ASIA PACIFIC: MARKET FOR OTHER SOURCES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 81 LATIN AMERICA: MARKET FOR OTHER SOURCES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 82 MIDDLE EAST: MARKET FOR OTHER SOURCES, BY REGION, 2022-2029 (USD MILLION)
TABLE 83 GCC COUNTRIES: MARKET FOR OTHER SOURCES, BY COUNTRY, 2022-2029 (USD MILLION)

9 MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA (Page No. - 126)
9.1 INTRODUCTION
TABLE 84 MONOCLONAL ANTIBODY THERAPEUTICS INDUSTRY, BY THERAPY AREA, 2022-2029 (USD MILLION)
9.2 INFLAMMATORY & AUTOIMMUNE DISORDERS
9.2.1 RISING DEMAND FOR TARGETED THERAPEUTICS TO DRIVE MARKET
TABLE 85 MARKET FOR INFLAMMATORY & AUTOIMMUNE DISORDERS, BY REGION, 2022-2029 (USD MILLION)
TABLE 86 NORTH AMERICA: MARKET FOR INFLAMMATORY & AUTOIMMUNE DISORDERS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 87 EUROPE: MARKET FOR INFLAMMATORY & AUTOIMMUNE DISORDERS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 88 ASIA PACIFIC: MARKET FOR INFLAMMATORY & AUTOIMMUNE DISORDERS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 89 LATIN AMERICA: THERAPEUTICS MARKET FOR INFLAMMATORY & AUTOIMMUNE DISORDERS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 90 MIDDLE EAST: MARKET FOR INFLAMMATORY & AUTOIMMUNE DISORDERS, BY REGION, 2022-2029 (USD MILLION)
TABLE 91 GCC COUNTRIES: MARKET FOR INFLAMMATORY & AUTOIMMUNE DISORDERS, BY COUNTRY, 2022-2029 (USD MILLION)
9.3 ONCOLOGY
9.3.1 GROWING FOCUS ON ONCOLOGY THERAPEUTICS TO PROPEL MARKET
TABLE 92 MARKET FOR CANCER, BY REGION, 2022-2029 (USD MILLION)
TABLE 93 NORTH AMERICA: MARKET FOR CANCER, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 94 EUROPE: MARKET FOR CANCER, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 95 ASIA PACIFIC: MARKET FOR CANCER, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 96 LATIN AMERICA: MARKET FOR CANCER, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 97 MIDDLE EAST: MARKET FOR CANCER, BY REGION, 2022−2029 (USD MILLION)
TABLE 98 GCC COUNTRIES: MARKET FOR CANCER, BY COUNTRY, 2022−2029 (USD MILLION)
9.4 HEMATOLOGY
9.4.1 RISING INCIDENCE OF THROMBOTIC DISORDERS TO SUPPORT MARKET GROWTH
TABLE 99 MARKET FOR HEMATOLOGY, BY REGION, 2022−2029 (USD MILLION)
TABLE 100 NORTH AMERICA: MARKET FOR HEMATOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 101 EUROPE: MARKET FOR HEMATOLOGY, BY COUNTRY, 2022−2029 (USD MILLION)
TABLE 102 ASIA PACIFIC: MARKET FOR HEMATOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 103 LATIN AMERICA: MARKET FOR HEMATOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 104 MIDDLE EAST: MARKET FOR HEMATOLOGY, BY REGION, 2022-2029 (USD MILLION)
TABLE 105 GCC COUNTRIES: MARKET FOR HEMATOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
9.5 OPHTHALMOLOGY
9.5.1 RISING PREVALENCE OF AGE-RELATED MACULAR DEGENERATION TO BOOST DEMAND
TABLE 106 MARKET FOR OPHTHALMOLOGY, BY REGION, 2022-2029 (USD MILLION)
TABLE 107 NORTH AMERICA: MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 108 EUROPE: MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 109 ASIA PACIFIC: MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 110 LATIN AMERICA: MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 111 MIDDLE EAST: MARKET FOR OPHTHALMOLOGY, BY REGION, 2022-2029 (USD MILLION)
TABLE 112 GCC COUNTRIES: MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
9.6 OTHER THERAPY AREAS
TABLE 113 MARKET FOR OTHER THERAPY AREAS, BY REGION, 2022-2029 (USD MILLION)
TABLE 114 NORTH AMERICA: MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 115 EUROPE: MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 116 ASIA PACIFIC: MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 117 LATIN AMERICA: MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 118 MIDDLE EAST: MARKET FOR OTHER THERAPY AREAS, BY REGION, 2022-2029 (USD MILLION)
TABLE 119 GCC COUNTRIES: MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2022-2029 (USD MILLION)

10 MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER (Page No. - 146)
10.1 INTRODUCTION
TABLE 120 MONOCLONAL ANTIBODY THERAPEUTICS INDUSTRY, BY END USER, 2022-2029 (USD MILLION)
10.2 HOSPITALS
10.2.1 AVAILABILITY OF ADVANCED HEALTHCARE INFRASTRUCTURE TO PROPEL MARKET
TABLE 121 MARKET FOR HOSPITALS, BY REGION, 2022-2029 (USD MILLION)
TABLE 122 NORTH AMERICA: MARKET FOR HOSPITALS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 123 EUROPE: MARKET FOR HOSPITALS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 124 ASIA PACIFIC: MARKET FOR HOSPITALS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 125 LATIN AMERICA: MARKET FOR HOSPITALS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 126 MIDDLE EAST: MARKET FOR HOSPITALS, BY REGION, 2022-2029 (USD MILLION)
TABLE 127 GCC COUNTRIES: MARKET FOR HOSPITALS, BY COUNTRY, 2022-2029 (USD MILLION)
10.3 LONG-TERM CARE FACILITIES
10.3.1 SPECIALIZED CARE AND CONTINUOUS MONITORING ADVANTAGES TO DRIVE MARKET
TABLE 128 MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2022-2029 (USD MILLION)
TABLE 129 NORTH AMERICA: MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 130 EUROPE: MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 131 ASIA PACIFIC: MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 132 LATIN AMERICA: MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 133 MIDDLE EAST: MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2022-2029 (USD MILLION)
TABLE 134 GCC COUNTRIES: MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022-2029 (USD MILLION)
10.4 OTHER END USERS
TABLE 135 MARKET FOR OTHER END USERS, BY REGION, 2022-2029 (USD MILLION)
TABLE 136 NORTH AMERICA: MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 137 EUROPE: MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 138 ASIA PACIFIC: MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 139 LATIN AMERICA: MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 140 MIDDLE EAST: MARKET FOR OTHER END USERS, BY REGION, 2022-2029 (USD MILLION)
TABLE 141 GCC COUNTRIES: MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)

11 MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY REGION (Page No. - 158)
11.1 INTRODUCTION
TABLE 142 MONOCLONAL ANTIBODY THERAPEUTICS INDUSTRY, BY REGION, 2022-2029 (USD MILLION)
11.2 NORTH AMERICA
FIGURE 32 NORTH AMERICA: MARKET SNAPSHOT
TABLE 143 NORTH AMERICA: MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 144 NORTH AMERICA: MARKET, BY PRODUCTION METHOD, 2022-2029 (USD MILLION)
TABLE 145 NORTH AMERICA: MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
TABLE 146 NORTH AMERICA: MARKET, BY SOURCE, 2022-2029 (USD MILLION)
TABLE 147 NORTH AMERICA: MARKET, BY THERAPY AREA, 2022-2029 (USD MILLION)
TABLE 148 NORTH AMERICA: MARKET, BY END USER, 2022-2029 (USD MILLION)
11.2.1 NORTH AMERICA: RECESSION IMPACT
11.2.2 US
11.2.2.1 Rising regulatory approvals for product commercialization to propel market
TABLE 149 PRODUCT APPROVALS FOR MAB THERAPEUTICS BY US FDA
TABLE 150 US: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022-2029 (USD MILLION)
TABLE 151 US: MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
TABLE 152 US: MARKET, BY SOURCE, 2022-2029 (USD MILLION)
TABLE 153 US: MARKET, BY THERAPY AREA, 2022-2029 (USD MILLION)
TABLE 154 US: MARKET, BY END USER, 2022-2029 (USD MILLION)
11.2.3 CANADA
11.2.3.1 Rising investments in antibody research to support market growth
TABLE 155 CANADA: MARKET, BY PRODUCTION METHOD, 2022-2029 (USD MILLION)
TABLE 156 CANADA: MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
TABLE 157 CANADA: MARKET, BY SOURCE, 2022-2029 (USD MILLION)
TABLE 158 CANADA: MARKET, BY THERAPY AREA, 2022-2029 (USD MILLION)
TABLE 159 CANADA: MARKET, BY END USER, 2022-2029 (USD MILLION)
11.3 EUROPE
FIGURE 33 EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET SNAPSHOT
TABLE 160 EUROPE: MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 161 EUROPE: MARKET, BY PRODUCTION METHOD, 2022-2029 (USD MILLION)
TABLE 162 EUROPE: MARKET, BY SOURCE, 2022-2029 (USD MILLION)
TABLE 163 EUROPE: MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
TABLE 164 EUROPE: MARKET, BY THERAPY AREA, 2022-2029 (USD MILLION)
TABLE 165 EUROPE: MARKET, BY END USER, 2022-2029 (USD MILLION)
11.3.1 EUROPE: RECESSION IMPACT
11.3.2 GERMANY
11.3.2.1 Rising number of clinical trials for mAb therapeutics to drive market
TABLE 166 GERMANY: MARKET, BY PRODUCTION METHOD, 2022-2029 (USD MILLION)
TABLE 167 GERMANY: MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
TABLE 168 GERMANY: MARKET, BY SOURCE, 2022-2029 (USD MILLION)
TABLE 169 GERMANY: MARKET, BY THERAPY AREA, 2022-2029 (USD MILLION)
TABLE 170 GERMANY: MARKET, BY END USER, 2022-2029 (USD MILLION)
11.3.3 UK
11.3.3.1 Increasing R&D initiatives by pharmaceutical & biotechnology companies to support market growth
TABLE 171 UK: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040
TABLE 172 UK: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022-2029 (USD MILLION)
TABLE 173 UK: MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
TABLE 174 UK: MARKET, BY SOURCE, 2022-2029 (USD MILLION)
TABLE 175 UK: MARKET, BY THERAPY AREA, 2022-2029 (USD MILLION)
TABLE 176 UK: MARKET, BY END USER, 2022-2029 (USD MILLION)
11.3.4 FRANCE
11.3.4.1 Favorable reimbursement policies for therapeutic treatments to propel market
TABLE 177 FRANCE: MARKET, BY PRODUCTION METHOD, 2022-2029 (USD MILLION)
TABLE 178 FRANCE: MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
TABLE 179 FRANCE: MARKET, BY SOURCE, 2022-2029 (USD MILLION)
TABLE 180 FRANCE: MARKET, BY THERAPY AREA, 2022-2029 (USD MILLION)
TABLE 181 FRANCE: MARKET, BY END USER, 2022-2029 (USD MILLION)
11.3.5 ITALY
11.3.5.1 Growth in life sciences industry to boost demand
TABLE 182 ITALY: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022-2029 (USD MILLION)
TABLE 183 ITALY: MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
TABLE 184 ITALY: MARKET, BY SOURCE, 2022-2029 (USD MILLION)
TABLE 185 ITALY: MARKET, BY THERAPY AREA, 2022-2029 (USD MILLION)
TABLE 186 ITALY: MARKET, BY END USER, 2022-2029 (USD MILLION)
11.3.6 SPAIN
11.3.6.1 Growing focus on research for biomaterial development to drive market
TABLE 187 SPAIN: MARKET, BY PRODUCTION METHOD, 2022-2029 (USD MILLION)
TABLE 188 SPAIN: MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
TABLE 189 SPAIN: MARKET, BY SOURCE, 2022-2029 (USD MILLION)
TABLE 190 SPAIN: MARKET, BY THERAPY AREA, 2022-2029 (USD MILLION)
TABLE 191 SPAIN: MARKET, BY END USER, 2022-2029 (USD MILLION)
11.3.7 TURKEY
11.3.7.1 Rising investments in R&D for healthcare infrastructure to support market growth
TABLE 192 TURKEY: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022-2029 (USD MILLION)
TABLE 193 TURKEY: MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
TABLE 194 TURKEY: MARKET, BY SOURCE, 2022-2029 (USD MILLION)
TABLE 195 TURKEY: MARKET, BY THERAPY AREA, 2022-2029 (USD MILLION)
TABLE 196 TURKEY: MARKET, BY END USER, 2022-2029 (USD MILLION)
11.3.8 REST OF EUROPE
TABLE 197 REST OF EUROPE: MARKET, BY PRODUCTION METHOD, 2022-2029 (USD MILLION)
TABLE 198 REST OF EUROPE: MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
TABLE 199 REST OF EUROPE: MARKET, BY SOURCE, 2022-2029 (USD MILLION)
TABLE 200 REST OF EUROPE: MARKET, BY THERAPY AREA, 2022-2029 (USD MILLION)
TABLE 201 REST OF EUROPE: MARKET, BY END USER, 2022-2029 (USD MILLION)
11.4 ASIA PACIFIC
TABLE 202 ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 203 ASIA PACIFIC: MARKET, BY PRODUCTION METHOD, 2022-2029 (USD MILLION)
TABLE 204 ASIA PACIFIC: MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
TABLE 205 ASIA PACIFIC: MARKET, BY SOURCE, 2022-2029 (USD MILLION)
TABLE 206 ASIA PACIFIC: MARKET, BY THERAPY AREA, 2022-2029 (USD MILLION)
TABLE 207 ASIA PACIFIC: MARKET, BY END USER, 2022-2029 (USD MILLION)
11.4.1 ASIA PACIFIC: RECESSION IMPACT
11.4.2 CHINA
11.4.2.1 Growing preference for precision medicines to propel market
TABLE 208 CHINA: MARKET, BY PRODUCTION METHOD, 2022-2029 (USD MILLION)
TABLE 209 CHINA: MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
TABLE 210 CHINA: MARKET, BY SOURCE, 2022-2029 (USD MILLION)
TABLE 211 CHINA: MARKET, BY THERAPY AREA, 2022-2029 (USD MILLION)
TABLE 212 CHINA: MARKET, BY END USER, 2022-2029 (USD MILLION)
11.4.3 JAPAN
11.4.3.1 Availability of healthcare insurance and favorable regulatory environment to propel market
TABLE 213 JAPAN: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022-2029 (USD MILLION)
TABLE 214 JAPAN: MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
TABLE 215 JAPAN: MARKET, BY SOURCE, 2022-2029 (USD MILLION)
TABLE 216 JAPAN: MARKET, BY THERAPY AREA, 2022-2029 (USD MILLION)
TABLE 217 JAPAN: MARKET, BY END USER, 2022-2029 (USD MILLION)
11.4.4 INDIA
11.4.4.1 Increasing incidence of chronic diseases and high growth in pharma R&D to fuel market
TABLE 218 INDIA: MARKET, BY PRODUCTION METHOD, 2022-2029 (USD MILLION)
TABLE 219 INDIA: MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
TABLE 220 INDIA: MARKET, BY SOURCE, 2022-2029 (USD MILLION)
TABLE 221 INDIA: MARKET, BY THERAPY AREA, 2022-2029 (USD MILLION)
TABLE 222 INDIA: MARKET, BY END USER, 2022-2029 (USD MILLION)
11.4.5 SOUTH KOREA
11.4.5.1 Strategic initiatives by key players to support market growth
TABLE 223 SOUTH KOREA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022-2029 (USD MILLION)
TABLE 224 SOUTH KOREA: MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
TABLE 225 SOUTH KOREA: MARKET, BY SOURCE, 2022-2029 (USD MILLION)
TABLE 226 SOUTH KOREA: MARKET, BY THERAPY AREA, 2022-2029 (USD MILLION)
TABLE 227 SOUTH KOREA: MARKET, BY END USER, 2022-2029 (USD MILLION)
11.4.6 INDONESIA
11.4.6.1 Funding initiatives and key product launches to support market growth
TABLE 228 INDONESIA: MARKET, BY PRODUCTION METHOD, 2022-2029 (USD MILLION)
TABLE 229 INDONESIA: MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
TABLE 230 INDONESIA: MARKET, BY SOURCE, 2022-2029 (USD MILLION)
TABLE 231 INDONESIA: MARKET, BY THERAPY AREA, 2022-2029 (USD MILLION)
TABLE 232 INDONESIA: MARKET, BY END USER, 2022-2029 (USD MILLION)
11.4.7 MALAYSIA
11.4.7.1 Increasing focus on government-funded initiatives for management of chronic ailments to support market growth
TABLE 233 MALAYSIA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022-2029 (USD MILLION)
TABLE 234 MALAYSIA: MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
TABLE 235 MALAYSIA: MARKET, BY SOURCE, 2022-2029 (USD MILLION)
TABLE 236 MALAYSIA: MARKET, BY THERAPY AREA, 2022-2029 (USD MILLION)
TABLE 237 MALAYSIA: MARKET, BY END USER, 2022-2029 (USD MILLION)
11.4.8 REST OF ASIA PACIFIC
TABLE 238 REST OF ASIA PACIFIC: MARKET, BY PRODUCTION METHOD, 2022-2029 (USD MILLION)
TABLE 239 REST OF ASIA PACIFIC: MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
TABLE 240 REST OF ASIA PACIFIC: MARKET, BY SOURCE, 2022-2029 (USD MILLION)
TABLE 241 REST OF ASIA PACIFIC: MARKET, BY THERAPY AREA, 2022-2029 (USD MILLION)
TABLE 242 REST OF ASIA PACIFIC: MARKET, BY END USER, 2022-2029 (USD MILLION)
11.5 LATIN AMERICA
TABLE 243 LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 244 LATIN AMERICA: MARKET, BY PRODUCTION METHOD, 2022-2029 (USD MILLION)
TABLE 245 LATIN AMERICA: MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
TABLE 246 LATIN AMERICA: MARKET, BY SOURCE, 2022-2029 (USD MILLION)
TABLE 247 LATIN AMERICA: MARKET, BY THERAPY AREA, 2022-2029 (USD MILLION)
TABLE 248 LATIN AMERICA: MARKET, BY END USER, 2022-2029 (USD MILLION)
11.5.1 LATIN AMERICA: RECESSION IMPACT
11.5.2 BRAZIL
11.5.2.1 Increasing incidence of chronic & infectious diseases to drive market
TABLE 249 BRAZIL: MARKET, BY PRODUCTION METHOD, 2022-2029 (USD MILLION)
TABLE 250 BRAZIL: MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
TABLE 251 BRAZIL: MARKET, BY SOURCE, 2022-2029 (USD MILLION)
TABLE 252 BRAZIL: MARKET, BY THERAPY AREA, 2022-2029 (USD MILLION)
TABLE 253 BRAZIL: MARKET, BY END USER, 2022-2029 (USD MILLION)
11.5.3 REST OF LATIN AMERICA
TABLE 254 REST OF LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022-2029 (USD MILLION)
TABLE 255 REST OF LATIN AMERICA: MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
TABLE 256 REST OF LATIN AMERICA: MARKET, BY SOURCE, 2022-2029 (USD MILLION)
TABLE 257 REST OF LATIN AMERICA: MARKET, BY THERAPY AREA, 2022-2029 (USD MILLION)
TABLE 258 REST OF LATIN AMERICA: MARKET, BY END USER, 2022-2029 (USD MILLION)
11.6 MIDDLE EAST
TABLE 259 MIDDLE EAST: MARKET, BY REGION, 2022-2029 (USD MILLION)
TABLE 260 MIDDLE EAST: MARKET, BY PRODUCTION METHOD, 2022-2029 (USD MILLION)
TABLE 261 MIDDLE EAST: MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
TABLE 262 MIDDLE EAST: MARKET, BY SOURCE, 2022-2029 (USD MILLION)
TABLE 263 MIDDLE EAST: MARKET, BY THERAPY AREA, 2022-2029 (USD MILLION)
TABLE 264 MIDDLE EAST: MARKET, BY END USER, 2022-2029 (USD MILLION)
11.6.1 MIDDLE EAST: RECESSION IMPACT
11.6.2 GCC COUNTRIES
TABLE 265 GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 266 GCC COUNTRIES: MARKET, BY PRODUCTION METHOD, 2022-2029 (USD MILLION)
TABLE 267 GCC COUNTRIES: MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
TABLE 268 GCC COUNTRIES: MARKET, BY SOURCE, 2022-2029 (USD MILLION)
TABLE 269 GCC COUNTRIES: MARKET, BY THERAPY AREA, 2022-2029 (USD MILLION)
TABLE 270 GCC COUNTRIES: MARKET, BY END USER, 2022-2029 (USD MILLION)
11.6.2.1 Saudi Arabia
11.6.2.1.1 Rising prevalence of CVD to support market growth
TABLE 271 SAUDI ARABIA: MARKET, BY PRODUCTION METHOD, 2022-2029 (USD MILLION)
TABLE 272 SAUDI ARABIA: MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
TABLE 273 SAUDI ARABIA: MARKET, BY SOURCE, 2022-2029 (USD MILLION)
TABLE 274 SAUDI ARABIA: MARKET, BY THERAPY AREA, 2022-2029 (USD MILLION)
TABLE 275 SAUDI ARABIA: MARKET, BY END USER, 2022-2029 (USD MILLION)
11.6.2.2 United Arab Emirates
11.6.2.2.1 Rising prevalence of diabetes to boost demand
TABLE 276 UNITED ARAB EMIRATES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022-2029 (USD MILLION)
TABLE 277 UNITED ARAB EMIRATES: MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
TABLE 278 UNITED ARAB EMIRATES: MARKET, BY SOURCE, 2022-2029 (USD MILLION)
TABLE 279 UNITED ARAB EMIRATES: MARKET, BY THERAPY AREA, 2022-2029 (USD MILLION)
TABLE 280 UNITED ARAB EMIRATES: MARKET, BY END USER, 2022-2029 (USD MILLION)
11.6.2.3 Other GCC countries
TABLE 281 OTHER GCC COUNTRIES: MARKET, BY PRODUCTION METHOD, 2022-2029 (USD MILLION)
TABLE 282 OTHER GCC COUNTRIES: MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
TABLE 283 OTHER GCC COUNTRIES: MARKET, BY SOURCE, 2022-2029 (USD MILLION)
TABLE 284 OTHER GCC COUNTRIES: MARKET, BY THERAPY AREA, 2022-2029 (USD MILLION)
TABLE 285 OTHER GCC COUNTRIES: MARKET, BY END USER, 2022-2029 (USD MILLION)
11.6.3 REST OF MIDDLE EAST
TABLE 286 REST OF MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022-2029 (USD MILLION)
TABLE 287 REST OF MIDDLE EAST: MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
TABLE 288 REST OF MIDDLE EAST: MARKET, BY SOURCE, 2022-2029 (USD MILLION)
TABLE 289 REST OF MIDDLE EAST: MARKET, BY THERAPY AREA, 2022-2029 (USD MILLION)
TABLE 290 REST OF MIDDLE EAST: MARKET, BY END USER, 2022-2029 (USD MILLION)
11.7 AFRICA
11.7.1 HIGH INVESTMENTS IN HEALTHCARE R&D TO SUPPORT MARKET GROWTH
TABLE 291 AFRICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022-2029 (USD MILLION)
TABLE 292 AFRICA: MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
TABLE 293 AFRICA: MARKET, BY SOURCE, 2022-2029 (USD MILLION)
TABLE 294 AFRICA: MARKET, BY THERAPY AREA, 2022-2029 (USD MILLION)
TABLE 295 AFRICA: MARKET, BY END USER, 2022-2029 (USD MILLION)
11.7.2 AFRICA: RECESSION IMPACT

12 COMPETITIVE LANDSCAPE (Page No. - 238)
12.1 INTRODUCTION
12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
FIGURE 34 STRATEGIES ADOPTED BY KEY PLAYERS IN MONOCLONAL ANTIBODY THERAPEUTICS MARKET
12.3 REVENUE SHARE ANALYSIS
FIGURE 35 REVENUE SHARE ANALYSIS OF KEY PLAYERS (2020−2023)
12.4 MARKET SHARE ANALYSIS
FIGURE 36 MARKET SHARE ANALYSIS OF KEY PLAYERS (2023)
TABLE 296 MONOCLONAL ANTIBODY THERAPEUTICS INDUSTRY: DEGREE OF COMPETITION
12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS
12.5.1 STARS
12.5.2 EMERGING LEADERS
12.5.3 PERVASIVE PLAYERS
12.5.4 PARTICIPANTS
FIGURE 37 MONOCLONAL ANTIBODY THERAPEUTICS INDUSTRY: COMPANY EVALUATION MATRIX FOR KEY PLAYERS (2023)
12.5.5 COMPANY FOOTPRINT
FIGURE 38 COMPANY FOOTPRINT (15 COMPANIES)
12.5.5.1 Type footprint
TABLE 297 TYPE FOOTPRINT (15 COMPANIES)
12.5.5.2 Regional footprint
TABLE 298 REGIONAL FOOTPRINT (15 COMPANIES)
12.6 COMPANY EVALUATION MATRIX: STARTUP/SME PLAYERS
12.6.1 PROGRESSIVE COMPANIES
12.6.2 DYNAMIC COMPANIES
12.6.3 RESPONSIVE COMPANIES
12.6.4 STARTING BLOCKS
FIGURE 39 MONOCLONAL ANTIBODY THERAPEUTICS INDUSTRY: COMPANY EVALUATION MATRIX FOR STARTUPS/SMES (2023)
12.7 COMPETITIVE BENCHMARKING OF STARTUP/SME PLAYERS
TABLE 299 MONOCLONAL ANTIBODY THERAPEUTICS INDUSTRY: DETAILED LIST OF KEY STARTUP/SME PLAYERS
TABLE 300 MONOCLONAL ANTIBODY THERAPEUTICS INDUSTRY: COMPETITIVE BENCHMARKING OF STARTUP/SME PLAYERS
12.8 VALUATION AND FINANCIAL METRICS OF MONOCLONAL ANTIBODY THERAPEUTIC VENDORS
FIGURE 40 EV/EBITDA OF KEY VENDORS
FIGURE 41 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
12.9 BRAND/PRODUCT COMPARATIVE ANALYSIS
12.9.1 BRAND/PRODUCT COMPARATIVE ANALYSIS, BY COMPANY AND SOURCE
FIGURE 42 BRAND/PRODUCT COMPARATIVE ANALYSIS, BY COMPANY AND SOURCE
12.9.1.1 F. Hoffmann-La Roche Ltd.
12.9.1.2 Johnson & Johnson Services, Inc.
12.9.1.3 Merck & Co., Inc.
12.9.1.4 AbbVie inc.
12.9.1.5 Sanofi
12.9.2 BRAND/PRODUCT COMPARATIVE ANALYSIS, BY COMPANY AND HUMAN SOURCE
FIGURE 43 BRAND/PRODUCT COMPARATIVE ANALYSIS, BY COMPANY AND HUMAN SOURCE
12.9.2.1 AstraZeneca
12.9.2.2 Bristol Myers Squibb Company
12.9.2.3 Novartis AG
12.10 COMPETITIVE SCENARIO
12.10.1 PRODUCT LAUNCHES & APPROVALS
TABLE 301 MONOCLONAL ANTIBODY THERAPEUTICS INDUSTRY: PRODUCT LAUNCHES & APPROVALS (JANUARY 2021−JANUARY 2024)
12.10.2 DEALS
TABLE 302 MONOCLONAL ANTIBODY THERAPEUTICS INDUSTRY: DEALS (JANUARY 2021−JANUARY 2024)
12.10.3 OTHER DEVELOPMENTS
TABLE 303 MONOCLONAL ANTIBODY THERAPEUTICS MARKET: OTHER DEVELOPMENTS (JANUARY 2021−JANUARY 2024)

13 COMPANY PROFILES (Page No. - 258)
(Business overview, Products/Services offered, Recent developments & MnM View)*
13.1 KEY PLAYERS
13.1.1 F. HOFFMANN-LA ROCHE LTD.
TABLE 304 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
FIGURE 44 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022)
TABLE 305 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS/SERVICES OFFERED
TABLE 306 F. HOFFMAN LA ROCHE LTD.: PRODUCT LAUNCHES & APPROVALS
TABLE 307 F. HOFFMAN LA ROCHE LTD.: DEALS
13.1.2 JOHNSON & JOHNSON SERVICES, INC.
TABLE 308 JOHNSON & JOHNSON SERVICES, INC.: COMPANY OVERVIEW
FIGURE 45 JOHNSON & JOHNSON SERVICES, INC.: COMPANY SNAPSHOT (2022)
TABLE 309 JOHNSON & JOHNSON SERVICES, INC.: PRODUCTS/SERVICES OFFERED
TABLE 310 JOHNSON & JOHNSON SERVICES, INC.: PRODUCT APPROVALS
13.1.3 MERCK & CO., INC.
TABLE 311 MERCK & CO., INC.: COMPANY OVERVIEW
FIGURE 46 MERCK & CO., INC COMPANY SNAPSHOT (2022)
TABLE 312 MERCK & CO., INC.: PRODUCTS/SERVICES OFFERED
TABLE 313 MERCK & CO., INC.: PRODUCT APPROVALS
13.1.4 ABBVIE INC.
TABLE 314 ABBVIE INC.: COMPANY OVERVIEW
FIGURE 47 ABBVIE INC.: COMPANY SNAPSHOT (2022)
TABLE 315 ABBVIE INC.: PRODUCTS /SERVICES OFFERED
TABLE 316 ABBVIE INC.: PRODUCT APPROVALS
TABLE 317 ABBVIE INC.: DEALS
13.1.5 BRISTOL-MYERS SQUIBB COMPANY
TABLE 318 BRISTOL-MYERS SQUIBB COMPANY: COMPANY OVERVIEW
FIGURE 48 BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT (2022)
TABLE 319 BRISTOL-MYERS SQUIBB COMPANY: PRODUCTS/SERVICES OFFERED
TABLE 320 BRISTOL-MYERS SQUIBB COMPANY: PRODUCT APPROVALS
TABLE 321 BRISTOL-MYERS SQUIBB COMPANY: DEALS
TABLE 322 BRISTOL-MYERS SQUIBB COMPANY: OTHER DEVELOPMENTS
13.1.6 ASTRAZENECA
TABLE 323 ASTRAZENECA: COMPANY OVERVIEW
FIGURE 49 ASTRAZENECA: COMPANY SNAPSHOT (2022)
TABLE 324 ASTRAZENECA: PRODUCTS/SERVICES OFFERED
TABLE 325 ASTRAZENECA: PRODUCT APPROVALS
TABLE 326 ASTRAZENECA: DEALS
13.1.7 SANOFI
TABLE 327 SANOFI: COMPANY OVERVIEW
FIGURE 50 SANOFI: COMPANY SNAPSHOT (2022)
TABLE 328 SANOFI: PRODUCTS/SERVICES OFFERED
TABLE 329 SANOFI: PRODUCT APPROVALS
TABLE 330 SANOFI: DEALS
13.1.8 NOVARTIS AG
TABLE 331 NOVARTIS AG: COMPANY OVERVIEW
FIGURE 51 NOVARTIS AG: COMPANY SNAPSHOT (2022)
TABLE 332 NOVARTIS AG: PRODUCTS/SERVICES OFFERED
TABLE 333 NOVARTIS AG: PRODUCT APPROVALS
TABLE 334 NOVARTIS AG: DEALS
TABLE 335 NOVARTIS AG: OTHER DEVELOPMENTS
13.1.9 AMGEN INC.
TABLE 336 AMGEN INC.: COMPANY OVERVIEW
FIGURE 52 AMGEN INC.: COMPANY SNAPSHOT (2022)
TABLE 337 AMGEN INC.: PRODUCTS/SERVICES OFFERED
TABLE 338 AMGEN INC.: PRODUCT APPROVALS
TABLE 339 AMGEN INC.: DEALS
TABLE 340 AMGEN INC.: EXPANSIONS
13.1.10 TAKEDA PHARMACEUTICAL COMPANY LIMITED
TABLE 341 TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY OVERVIEW
FIGURE 53 TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY SNAPSHOT (2022)
TABLE 342 TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCTS/SERVICES OFFERED
TABLE 343 TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCT APPROVALS
13.1.11 GSK PLC.
TABLE 344 GSK PLC.: COMPANY OVERVIEW
FIGURE 54 GSK PLC.: COMPANY SNAPSHOT (2022)
TABLE 345 GSK PLC.: PRODUCTS/SERVICES OFFERED
TABLE 346 GSK PLC.: PRODUCT APPROVALS
TABLE 347 GSK PLC.: DEALS
TABLE 348 GSK PLC.: OTHER DEVELOPMENTS
13.1.12 ELI LILLY AND COMPANY
TABLE 349 ELI LILLY AND COMPANY: COMPANY OVERVIEW
FIGURE 55 ELI LILLY AND COMPANY: COMPANY SNAPSHOT (2022)
TABLE 350 ELI LILLY AND COMPANY: PRODUCTS/SERVICES OFFERED
TABLE 351 ELI LILLY AND COMPANY: PRODUCT APPROVALS
TABLE 352 ELI LILLY AND COMPANY: DEALS
TABLE 353 ELI LILLY AND COMPANY: OTHER DEVELOPMENTS
13.1.13 REGENERON PHARMACEUTICALS INC.
TABLE 354 REGENERON PHARMACEUTICALS INC.: COMPANY OVERVIEW
FIGURE 56 REGENERON PHARMACEUTICALS INC.: COMPANY SNAPSHOT (2022)
TABLE 355 REGENERON PHARMACEUTICALS INC.: PRODUCTS/SERVICES OFFERED
TABLE 356 REGENERON PHARMACEUTICALS INC.: PRODUCT APPROVALS
TABLE 357 REGENERON PHARMACEUTICALS INC.: DEALS
13.1.14 BIOGEN
TABLE 358 BIOGEN: COMPANY OVERVIEW
FIGURE 57 BIOGEN: COMPANY SNAPSHOT (2022)
TABLE 359 BIOGEN: PRODUCTS/SERVICES OFFERED
TABLE 360 BIOGEN: PRODUCT APPROVALS
TABLE 361 BIOGEN: DEALS
13.1.15 UCB S.A.
TABLE 362 UCB S.A.: COMPANY OVERVIEW
FIGURE 58 UCB S.A.: COMPANY SNAPSHOT (2022)
TABLE 363 UCB S.A.: PRODUCTS/SERVICES OFFERED
TABLE 364 UCB S.A.: DEALS
TABLE 365 UCB S.A.: PRODUCT APPROVALS
13.2 OTHER PLAYERS
13.2.1 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
13.2.2 Y-MABS THERAPEUTICS, INC.
13.2.3 TEVA PHARMACEUTICAL INDUSTRIES LTD.
13.2.4 MERCK KGAA
13.2.5 KYOWA KIRIN CO., LTD.
13.2.6 SWEDISH ORPHAN BIOVITRUM AB
13.2.7 UNITED THERAPEUTICS CORPORATION
13.2.8 THERATECHNOLOGIES INC.
13.2.9 INCYTE
13.2.10 SUN PHARMACEUTICAL INDUSTRIES, INC.
*Details on Business overview, Products/Services offered, Recent developments & MnM View might not be captured in case of unlisted companies.

14 APPENDIX (Page No. - 343)
14.1 DISCUSSION GUIDE
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.3 CUSTOMIZATIONS OPTIONS
14.4 RELATED REPORTS
14.5 AUTHOR DETAILS